


IN THE CLAIMS

Please amend the claims as follows:

- 1.- (Currently Amended) ~~Sulfonamide compounds A sulfonamide of general formula (Ia),~~



(Ia)

wherein

R<sup>1</sup> represents a -NR<sup>7</sup>R<sup>8</sup> radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a -NR<sup>9</sup>R<sup>10</sup> group,

R<sup>7</sup> and R<sup>8</sup>, identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

with the proviso that R<sup>8</sup> and R<sup>9</sup> are not hydrogen at the same time, and if one of them, R<sup>8</sup> or R<sup>9</sup>, is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>4</sub> aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms,

or

R<sup>7</sup> and R<sup>8</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched, ~~optionally at least mono-substituted~~ aliphatic radical, optionally at least mono-substituted

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, ~~optionally at least mono-substituted~~ cycloalkyl ring,

optionally at least mono-substituted



and

n is 0,

a stereoisomer thereof, an enantiomer thereof, a diasteromer thereof, a racemate thereof, a pharmaceutically acceptable salt thereof, or mixtures thereof optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof.

2. (Currently Amended) The ~~compounds~~ compound according to claim 1, characterized in that ~~wherein~~ R<sup>1</sup> represents a ~~-NR<sup>7</sup>R<sup>8</sup>~~ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing 5- or 6-membered cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- or 6-membered;

~~preferably a NR<sup>7</sup>R<sup>8</sup> radical or a radical chosen from the group consisting of~~



Reply to Office Action of January 11, 2008

~~wherein, if present, the dotted line represents an optional chemical bond, and R<sup>19</sup> represents hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub>-alkyl radical or a benzyl radical, preferably hydrogen or a C<sub>1</sub>-C<sub>2</sub>-alkyl radical.~~

- 3.- (Currently Amended) The compounds compound according to claim 1 or 2, characterized in that wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C<sub>1-6</sub> alkyl radical, a linear or branched C<sub>2-6</sub> alkenyl radical, a linear or branched C<sub>2-6</sub> alkynyl radical, a linear or branched C<sub>1-6</sub> alkoxy, a linear or branched C<sub>1-6</sub> alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C<sub>3-8</sub> cycloaliphatic radical, a linear or branched C<sub>1-6</sub> alkylcarbonyl radical, phenylcarbonyl or an -NR<sup>9</sup>R<sup>10</sup> group;

~~preferably H, F, Cl, NO<sub>2</sub>, NH<sub>2</sub> or a C<sub>1-2</sub>-alkyl radical.~~






- 4.- (Currently Amended) The compounds compound according to one or more of claims 1 to 3, characterized in that claim 1, wherein R<sup>7</sup> and R<sup>8</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1-10</sub> alkyl radical, a linear or branched, optionally at least mono-substituted, C<sub>2-10</sub> alkenyl radical, or a linear or branched, optionally at least mono-substituted, C<sub>2-10</sub> alkynyl radical or

R<sup>7</sup> and R<sup>8</sup>, together with the bridging nitrogen form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at


least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5-, 6- or 7-membered.

5.- (Currently Amended) The ~~compounds~~ compound according to claim 4, characterized in that wherein R<sup>7</sup> and R<sup>8</sup>, identical or different, each represent hydrogen or a linear or branched C<sub>1-10</sub> alkyl radical or

R<sup>7</sup> and R<sup>8</sup>, together with the bridging nitrogen atom form a radical chosen from the group consisting of



and





wherein R<sup>20</sup>, if present, is hydrogen, a linear or branched C<sub>1-C<sub>6</sub></sub> alkyl radical or a benzyl radical, ~~preferably hydrogen, or a C<sub>4-C<sub>2</sub></sub> alkyl radical.~~

6.- (Currently Amended) The compounds compound according to one or more of claims 1 to 5 claim 1, characterized in that wherein R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>10</sub> alkyl radical, a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkenyl radical or a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkynyl radical or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system whereby the rings of the ring system are 5- 6- or 7-membered.

7.- (Currently Amended) The compounds compound according to claim 6, characterized in that wherein R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen or a linear or branched C<sub>1</sub>-C<sub>10</sub> alkyl radical, or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a radical chosen from a group consisting of



wherein R<sup>20</sup>, if present, is hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical or a benzyl radical, ~~preferably hydrogen, or a C<sub>1</sub>-C<sub>2</sub> alkyl radical.~~

8.- (Currently Amended) The ~~compounds compound~~ according to ~~one or more of claims 1-7, characterized in that claim 1, wherein~~ A and B, identical or different, each represent a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical, a linear or branched C<sub>2</sub>-C<sub>6</sub> alkenyl radical or a linear or branched C<sub>2</sub>-C<sub>6</sub> alkynyl radical,

~~preferably a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical, or~~

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring;

~~preferably a C<sub>3</sub>-C<sub>8</sub> cycloalkyl ring,~~

~~more preferably a cyclohexyl ring.~~

9.- (Currently Amended) The ~~compounds compound~~ to ~~one or more of claims 1-8, characterized in that the compound is claim 1, which is selected from a group consisting of~~

[1] 1-Cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-5-nitro-1H-indole,


[2] 5-Chloro-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole,

[3] 5-Amino-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole, and

[4] 1-Cyclohexanesulfonyl-5-fluoro-3-(1,2,3,5,8,8a-hexahydro-indolizine-7-yl)-1H-indole hydrochloride,

~~and their corresponding salts and solvates~~ a salt thereof, and a solvate thereof.

10.- (Withdrawn- Currently Amended) Sulfonamide compounds A sulfonamide compound of general formula (Ib),



(Ib)

wherein

R<sup>1</sup> is a -NR<sup>7</sup>R<sup>8</sup> radical,

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a -NR<sup>9</sup>R<sup>10</sup> group,

R<sup>7</sup> and R<sup>8</sup>, identical or different, each represent hydrogen or a saturated or

unsaturated, optionally at least mono-substituted linear or branched C<sub>1-4</sub> aliphatic radical,

R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

n is 0;

a stereoisomer thereof, an enantiomer thereof, a diasteromer thereof, a racemate thereof, a pharmaceutically acceptable salt thereof, or mixtures thereof optionally in

~~form of one of its stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof.~~

- 11.- (Withdrawn-Currently Amended) The ~~compounds compound~~ according to claim 10, characterized in that wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical, a linear or branched C<sub>2</sub>-C<sub>6</sub> alkenyl radical, a linear or branched C<sub>2</sub>-C<sub>6</sub> alkynyl radical, a linear or branched C<sub>1</sub>-C<sub>6</sub>-alkoxy, a linear or branched C<sub>1</sub>-C<sub>6</sub>-alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C<sub>3</sub>-C<sub>8</sub> cycloaliphatic radical, a linear or branched C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl radical, phenylcarbonyl or an -NR<sup>9</sup>R<sup>10</sup> group;  
~~preferably H, F, Cl, NO<sub>2</sub>, NH<sub>2</sub> or a C<sub>1</sub>-C<sub>2</sub> alkyl radical.~~
- 12.- (Withdrawn-Currently Amended) The ~~compounds compound~~ according to claim 10 or 11, characterized in that wherein R<sup>7</sup> and R<sup>8</sup>, identical or different, wherein R<sup>7</sup> and R<sup>8</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>4</sub> alkyl radical,


~~preferably hydrogen or a C<sub>1</sub>-C<sub>2</sub> alkyl radical~~, with the proviso that R<sup>7</sup> and R<sup>8</sup> are not hydrogen at the same time.

- 13.- (Withdrawn-Currently Amended) The ~~compounds~~ compound according to one or more of claims 10 to 12 claim 10, characterized in that R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>10</sub> alkyl radical, a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkenyl radical, or a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkynyl radical or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

- 14.- (Withdrawn-Currently Amended) The ~~compounds~~ compound according to claim 13, characterized in that wherein R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen or a linear or branched C<sub>1</sub>-C<sub>10</sub> alkyl radical, or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a radical chosen from a group consisting of




wherein R<sup>20</sup>, if present, represents hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical or a benzyl radical, ~~preferably hydrogen, or a C<sub>4</sub>-C<sub>2</sub> alkyl radical.~~

15.- (Currently Amended) The ~~compounds compound~~ according to ~~one or more of claims 10 to 14~~ claim 10, characterized in that ~~wherein~~ A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

~~preferably a C<sub>3</sub>-C<sub>8</sub>-cycloalkyl ring,~~


~~more preferably a cyclohexyl ring.~~

16.- (Currently Amended) A process for obtaining a sulfonamide derivative ~~compound~~ of general formula (Ia) and/or (Ib), according to ~~one or more of claims 1 to 15 according to claim 1, characterized in that~~ at least one compound of general formula (II), or one of its suitably protected derivatives a protected compound thereof,



(II)

wherein A and B have the meaning according to ~~one or more of claims 1 to 15~~ claim 1 and X is ~~an acceptable a~~ leaving group, preferably an halogen atom, more preferably chlorine, is reacted with at least one substituted indole of general formula (III)



(III)

wherein  $\text{R}^1\text{-R}^6$  and n have the meaning according to ~~one or more of claims 1 to 15~~ claim 1, or ~~one of their suitable a~~ protected derivatives compound thereof, and, if necessary, the protective groups are removed.

- 17.- (Currently Amended) A process for obtaining a sulfonamide derivative compound of general formula (Ia) and/or (Ib) according to ~~one or more of claims 1 to 15~~ claim 1, wherein one or more substituents  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  or  $\text{R}^6$  represent a nitro group, characterized in that and wherein a sulfonamide derivative compound of corresponding general formula (Ia) and/or (Ib) is reduced to a sulfonamide derivative compound of corresponding general formula (Ia) and/or (Ib), wherein one or more substituents  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  or  $\text{R}^6$  represent an amino group.
- 18.- (Currently Amended) A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general a salt of the compound of formula (Ia) and/or (Ib), according to one or more of claims 1 to 15, consisting of according to claim 1, the process comprising reacting at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) with a mineral acid or organic acid in a suitable solvent to form the salt of the compound of formula (Ia).

19.- (Currently Amended) A ~~medicament composition~~ comprising at least one compound according to ~~one or more of claims 1 to 9 and optionally to claim 1 and~~ one or more pharmacologically acceptable excipients.

20.- (Cancelled).

21. - (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for A method of regulating a 5-HT<sub>6</sub> receptor regulation in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate a 5 HT<sub>6</sub> receptor in the subject.~~

22.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of a A method of treating a disorder or disease related to food intake in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder or disease in the subject.~~

23.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the regulation of A method for regulating appetite in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate appetite in the subject.~~

24.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the maintenance, increase or~~

~~reduction of A method for regulating body weight in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate body weight in the subject.~~

- 25.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method of treating obesity in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat obesity in the subject.~~
- 26.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method of treating bulimia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat bulimia in the subject.~~
- 27.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating anorexia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat anorexia in the subject.~~
- 28.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating cachexia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat cachexia in the subject.~~

- 29.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat type II diabetes in the subject.~~
- 30.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the manufacture of a medicament for the prophylaxis and/or treatment of A method of treating a gastrointestinal tract disorder disorders in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.~~
- 31.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating irritable bowel syndrome in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat irritable bowel syndrome in the subject.~~
- 32.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating anxiety in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat anxiety in the subject.~~

- 33.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating depression in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat depression in the subject.~~
- 34.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders A method for treating bipolar disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.~~
35. - (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating cognitive memory disorder disorders in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.~~
- 36.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating senile dementia processes in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the senile dementia process in the subject.~~
- 37.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating Alzheimer's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.~~

- 38.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating Parkinson's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.~~
- 39.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating Huntington's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.~~
- 40.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating Multiple Sclerosis in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the multiple sclerosis in the subject.~~
- 41.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias-A method for treating dimensia in which a cognitive deficit predominates in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the dimensia in the subject.~~
- 42.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or~~

treatment of A method for treating psychosis in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat psychosis in the subject.

- 43.- (Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder) in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat infantile hyperkinesia in the subject.
- 44.- (Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders A method for treating a disorder of the central nervous system in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.
- 45.- (Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of A method for treating schizophrenia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat schizophrenia in the subject.
- 46.- (Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for cognitive enhancement A method of enhancing cognitive ability in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to enhance cognitive ability in the subject.

47. (Currently Amended) A ~~medicament composition~~ comprising at least one compound according to ~~one or more of claims 9 to 15~~ claim 9 and optionally at least one or more of pharmacologically acceptable excipients.
- 48.- (Cancelled)
- 49.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for 5-HT<sub>6</sub> receptor regulation.
- 50.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 9 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 51.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the regulation of appetite.
- 52.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.
- 53.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

- 54.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 55.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
- 56.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 57.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 58.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 59.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.

- 60.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 61.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
- 62.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 63.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 64.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 65.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.



- 66.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 67.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 68.- The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 69.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 70.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
- 71.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).

72.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.

73.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.

74. - (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for cognitive enhancement.

75. (New) The compound according to claim 1, wherein R<sup>1</sup> represents a NR<sup>7</sup>R<sup>8</sup> radical or a radical chosen from the group consisting of



wherein, if present, the dotted line represents an optional chemical bond, and R<sup>19</sup> represents hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical or a benzyl radical, preferably hydrogen or a C<sub>1</sub>-C<sub>2</sub> alkyl radical.

76. (New) The compound according to claim 1, wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, identical or different, each represent H, F, Cl, NO<sub>2</sub>, NH<sub>2</sub> or a C<sub>1-2</sub> alkyl radical.